BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 20495290)

  • 1. Erythrocyte alpha-tocopherol in breast cancer patients treated with letrozol.
    Melichar B; Plísek J; Hyspler R; Kalábová H; Kasparová M; Krcmová L; Studentová H; Solichová D
    J Nutr Sci Vitaminol (Tokyo); 2010; 56(2):98-103. PubMed ID: 20495290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of aromatase inhibitors on lipid metabolism, inflammatory response and antioxidant balance in patients with breast carcinoma.
    Melichar B; Kalábová H; Krcmová L; Urbánek L; Hyspler R; Solichová D; Melicharová K; Pecka M; Zadák Z
    Anticancer Res; 2009 Aug; 29(8):3337-46. PubMed ID: 19661353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA; Josse RG; Pritchard KI; Ingle JN; Martino S; Findlay BP; Shenkier TN; Tozer RG; Palmer MJ; Shepherd LE; Liu S; Tu D; Goss PE
    J Clin Oncol; 2006 Aug; 24(22):3629-35. PubMed ID: 16822845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
    Mouridsen H; Chaudri-Ross HA
    Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of neoadjuvant anastrozole and tamoxifen on circulating vascular endothelial growth factor and soluble vascular endothelial growth factor receptor 1 in breast cancer.
    Banerjee S; Pancholi S; A'hern R; Ghazoui Z; Smith IE; Dowsett M; Martin LA
    Clin Cancer Res; 2008 May; 14(9):2656-63. PubMed ID: 18451229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.
    Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE
    J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
    Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
    J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience of hormonal therapy with anastrozole for previously treated metastatic breast cancer.
    Lavrenkov K; Man S; Geffen DB; Cohen Y
    Isr Med Assoc J; 2002 Mar; 4(3):176-7. PubMed ID: 11908256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Superiority of letrozole to tamoxifen in the first-line treatment of advanced breast cancer: evidence from metastatic subgroups and a test of functional ability.
    Mouridsen H; Sun Y; Gershanovich M; Perez-Carrion R; Becquart D; Chaudri-Ross HA; Lang R
    Oncologist; 2004; 9(5):489-96. PubMed ID: 15477633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
    Boccardo F; Rubagotti A; Puntoni M; Guglielmini P; Amoroso D; Fini A; Paladini G; Mesiti M; Romeo D; Rinaldini M; Scali S; Porpiglia M; Benedetto C; Restuccia N; Buzzi F; Franchi R; Massidda B; Distante V; Amadori D; Sismondi P
    J Clin Oncol; 2005 Aug; 23(22):5138-47. PubMed ID: 16009955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
    Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
    BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial.
    Tominaga T; Kimijima I; Kimura M; Takatsuka Y; Takashima S; Nomura Y; Kasumi F; Yamaguchi A; Masuda N; Noguchi S; Eshima N
    Jpn J Clin Oncol; 2010 Jul; 40(7):627-33. PubMed ID: 20382637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
    J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum alpha-tocopherol, retinol and neopterin during paclitaxel/carboplatin chemotherapy.
    Melichar B; Kalábová H; Krcmová L; Urbánek L; Hyspler R; Malírova E; Solichová D
    Anticancer Res; 2007; 27(6C):4397-401. PubMed ID: 18214051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
    Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
    Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
    Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
    J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial.
    Forbes JF
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer.
    Sawada S; Sato K; Kusuhara M; Ayaori M; Yonemura A; Tamaki K; Hiraide H; Mochizuki H; Ohsuzu F
    Acta Oncol; 2005; 44(2):134-41. PubMed ID: 15788292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.